Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060469 | 0.89 | ALDH1A1 (0.30) | ALDH1A1TDP1TSHR | |
| SCHEMBL24607182 | 0.89 | CES2 (0.45) | CES2ALDH1A1TDP1TSHR | |
| SCHEMBL25654227 | 0.89 | CES2 (0.45) | CES2ALDH1A1TDP1TSHR | |
| SCHEMBL137776 | 0.81 | — | — | |
| SCHEMBL10212353 | 0.80 | PTGS1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL26724964 | 0.79 | CES2 (0.45) | CES2ALDH1A1TDP1 | |
| SCHEMBL13542695 | 0.79 | MEN1 (0.37) | CES2ALDH1A1TDP1TSHR | |
| SCHEMBL29866183 | 0.78 | CES2 (0.50) | CES2ALDH1A1TDP1TSHR | |
| Water SCHEMBL10891347 | 0.78 | CES2 (0.50) | CES2ALDH1A1TDP1TSHR | |
| Water SCHEMBL7571126 | 0.78 | CES2 (0.50) | CES2ALDH1A1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220395525-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2022-12-15 | — | — | US | disclosed |
| US-8163792-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | CES2 4805/4885ALDH1A1 3380/4885TDP1 370/4885 |
| US-20220395525-A1 | THERAPEUTIC DENDRIMER | DCK, PAICS, SAMHD1 | CES2 2727/4885ALDH1A1 1769/4885TDP1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.